Kyorin Pharmaceutical
4569.TPharmaceutical
Filed as KYORIN Holdings, Inc. (2022-06–2022-06), KYORIN Holdings,Inc. (2022-08–2023-02)
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥126.3bn | ¥130.1bn | ¥119.5bn | ¥113.3bn | ¥105.5bn | ¥102.9bn |
| Operating income | ¥3.6bn | ¥12.6bn | ¥6.2bnr | ¥5.1bn | ¥5.0bn | ¥5.8bn |
| Ordinary income | ¥4.0bn | ¥13.2bn | ¥6.8bnr | ¥5.8bn | ¥5.6bn | ¥6.4bn |
| Net income (owners) | ¥3.4bn | ¥9.1bn | ¥5.5bnr | ¥4.7bn | ¥3.9bn | ¥6.1bn |
| Total assets | ¥195.5bn | ¥193.6bn | ¥177.6bnr | ¥176.0bn | ¥171.9bn | ¥167.1bn |
| Net assets / equity | ¥142.4bn | ¥136.3bn | ¥130.7bnr | ¥125.5bn | ¥124.5bn | ¥124.7bn |
| Operating cash flow | ¥6.4bn | ¥3.5bn | ¥1.5bn | ¥2.0bn | ¥6.3bn | ¥5.2bn |
| EPS (basic) | ¥60.03 | ¥158.17 | ¥95.41r | ¥82.44 | ¥68.62 | ¥106.99 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 196 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 67 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 196 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 67 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 196 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 45 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 69 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 43 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 196 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 45 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 69 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 43 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 196 figures · EDINET |
21 more reports are still being processed.